Poxel S.A. (POXEL.PA)
EUR 0.13
(-0.94%)
EUR 0.13
(-0.94%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -35.09 Million EUR | -11.76% |
| 2022 | -31.39 Million EUR | -32.14% |
| 2021 | -23.76 Million EUR | 25.41% |
| 2020 | -31.85 Million EUR | -23.75% |
| 2019 | -25.74 Million EUR | -290.34% |
| 2018 | 13.52 Million EUR | 159.6% |
| 2017 | -22.69 Million EUR | 7.31% |
| 2016 | -24.48 Million EUR | -100.01% |
| 2015 | -12.24 Million EUR | 13.08% |
| 2014 | -14.08 Million EUR | 31.15% |
| 2013 | -20.45 Million EUR | -186.52% |
| 2012 | -7.13 Million EUR | 17.23% |
| 2011 | -8.62 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | - EUR | 100.0% |
| 2023 Q4 | -8.84 Million EUR | 0.0% |
| 2023 Q2 | -26.24 Million EUR | 0.0% |
| 2022 FY | -31.39 Million EUR | -32.14% |
| 2022 Q4 | -17.99 Million EUR | 0.0% |
| 2022 Q2 | -13.4 Million EUR | 0.0% |
| 2021 FY | -23.76 Million EUR | 25.41% |
| 2021 Q2 | -8.02 Million EUR | 0.0% |
| 2021 Q4 | -15.73 Million EUR | 0.0% |
| 2020 Q2 | -12.06 Million EUR | 0.0% |
| 2020 FY | -31.85 Million EUR | -23.75% |
| 2020 Q4 | -19.79 Million EUR | 0.0% |
| 2019 FY | -25.74 Million EUR | -290.34% |
| 2019 Q1 | -6.43 Million EUR | -8.07% |
| 2019 Q2 | -5.79 Million EUR | 10.0% |
| 2019 Q4 | -19.95 Million EUR | 0.0% |
| 2018 FY | 13.52 Million EUR | 159.6% |
| 2018 Q4 | -5.95 Million EUR | 0.0% |
| 2018 Q1 | 3.38 Million EUR | 126.81% |
| 2018 Q2 | 7.25 Million EUR | 114.6% |
| 2017 Q2 | -9.68 Million EUR | -73.43% |
| 2017 FY | -22.69 Million EUR | 7.31% |
| 2017 Q4 | -12.6 Million EUR | 0.0% |
| 2017 Q1 | -5.58 Million EUR | 53.82% |
| 2016 Q1 | -6.24 Million EUR | 10.98% |
| 2016 Q4 | -12.09 Million EUR | 0.0% |
| 2016 FY | -24.48 Million EUR | -100.01% |
| 2016 Q2 | -12.38 Million EUR | -98.48% |
| 2015 Q2 | -5.23 Million EUR | -59.74% |
| 2015 FY | -12.24 Million EUR | 13.08% |
| 2015 Q4 | -7.01 Million EUR | -114.1% |
| 2015 Q3 | -3.27 Million EUR | 37.4% |
| 2015 Q1 | -3.27 Million EUR | 0.33% |
| 2014 Q4 | -3.28 Million EUR | 9.09% |
| 2014 Q3 | -3.61 Million EUR | 66.53% |
| 2014 Q2 | -10.79 Million EUR | -198.81% |
| 2014 Q1 | -3.61 Million EUR | 78.83% |
| 2014 FY | -14.08 Million EUR | 31.15% |
| 2013 FY | -20.45 Million EUR | -186.52% |
| 2013 Q4 | -17.06 Million EUR | -233.79% |
| 2013 Q2 | -3.38 Million EUR | 33.79% |
| 2013 Q3 | -5.11 Million EUR | -51.04% |
| 2013 Q1 | -5.11 Million EUR | 0.0% |
| 2012 Q3 | -1.78 Million EUR | 0.0% |
| 2012 FY | -7.13 Million EUR | 17.23% |
| 2012 Q1 | -1.78 Million EUR | 0.0% |
| 2012 Q2 | -1.78 Million EUR | 0.0% |
| 2012 Q4 | -5.11 Million EUR | -186.52% |
| 2011 Q2 | -2.15 Million EUR | 0.0% |
| 2011 FY | -8.62 Million EUR | 0.0% |
| 2011 Q1 | -2.15 Million EUR | 0.0% |
| 2011 Q4 | -1.78 Million EUR | 17.23% |
| 2011 Q3 | -2.15 Million EUR | 0.0% |
| 2010 Q4 | -2.15 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -897.442% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 76.249% |
| Adocia SA | -21.16 Million EUR | -65.816% |
| Aelis Farma SA | -5.07 Million EUR | -591.02% |
| Biophytis S.A. | -17.02 Million EUR | -106.097% |
| Advicenne S.A. | -7.03 Million EUR | -399.076% |
| genOway Société anonyme | 1.56 Million EUR | 2338.489% |
| IntegraGen SA | -171.39 Thousand EUR | -20372.698% |
| Medesis Pharma S.A. | -3.95 Million EUR | -786.225% |
| Neovacs S.A. | -8.74 Million EUR | -301.329% |
| NFL Biosciences SA | -3.74 Million EUR | -836.864% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 44422.904% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -1006.609% |
| Sensorion SA | -22.06 Million EUR | -59.042% |
| Theranexus Société Anonyme | -6.82 Million EUR | -413.917% |
| TME Pharma N.V. | -6.73 Million EUR | -420.932% |
| Valbiotis SA | -7.36 Million EUR | -376.249% |
| TheraVet SA | -1.57 Million EUR | -2134.026% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -72.483% |
| argenx SE | -272.91 Million EUR | 87.143% |
| BioSenic S.A. | -28.77 Million EUR | -21.933% |
| Celyad Oncology SA | -8.44 Million EUR | -315.365% |
| DBV Technologies S.A. | -67.26 Million EUR | 47.837% |
| Galapagos NV | 211.69 Million EUR | 116.576% |
| Genfit S.A. | -28.89 Million EUR | -21.444% |
| GeNeuro SA | -14.75 Million EUR | -137.785% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -128.153% |
| Innate Pharma S.A. | -7.57 Million EUR | -363.54% |
| Inventiva S.A. | -110.42 Million EUR | 68.223% |
| MaaT Pharma SA | -19.71 Million EUR | -77.968% |
| MedinCell S.A. | -25.03 Million EUR | -40.147% |
| Nanobiotix S.A. | -39.7 Million EUR | 11.612% |
| Onward Medical N.V. | -36.18 Million EUR | 3.015% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -946.543% |
| OSE Immunotherapeutics SA | -23 Million EUR | -52.545% |
| Oxurion NV | -18.96 Million EUR | -84.986% |
| Pharming Group N.V. | -9.75 Million EUR | -259.654% |
| GenSight Biologics S.A. | -26.22 Million EUR | -33.829% |
| Transgene SA | -22.32 Million EUR | -57.157% |
| Financière de Tubize SA | 88.15 Million EUR | 139.807% |
| UCB SA | 343 Million EUR | 110.23% |
| Valneva SE | -101.42 Million EUR | 65.404% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | -23.809% |